CN111465402B - 用于制备类视黄醇x受体-特异性类视黄醇的化合物和合成方法 - Google Patents

用于制备类视黄醇x受体-特异性类视黄醇的化合物和合成方法 Download PDF

Info

Publication number
CN111465402B
CN111465402B CN201880074452.0A CN201880074452A CN111465402B CN 111465402 B CN111465402 B CN 111465402B CN 201880074452 A CN201880074452 A CN 201880074452A CN 111465402 B CN111465402 B CN 111465402B
Authority
CN
China
Prior art keywords
compound
formula
solvate
alkyl
preparing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880074452.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN111465402A (zh
Inventor
罗山赛·A·钱德拉拉特纳
维迪亚萨加尔·普拉迪普·伍里贡达
托马斯·杰克斯
彼得·韦德
安德鲁·汤普森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IO Therapeutics Inc
Original Assignee
IO Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IO Therapeutics Inc filed Critical IO Therapeutics Inc
Priority to CN202210482327.1A priority Critical patent/CN115010577A/zh
Publication of CN111465402A publication Critical patent/CN111465402A/zh
Application granted granted Critical
Publication of CN111465402B publication Critical patent/CN111465402B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/46—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid
    • C07C57/50—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid containing condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C29/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring
    • C07C29/32—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring increasing the number of carbon atoms by reactions without formation of -OH groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C29/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring
    • C07C29/44—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring increasing the number of carbon atoms by addition reactions, i.e. reactions involving at least one carbon-to-carbon double or triple bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C29/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring
    • C07C29/74—Separation; Purification; Use of additives, e.g. for stabilisation
    • C07C29/76—Separation; Purification; Use of additives, e.g. for stabilisation by physical treatment
    • C07C29/86—Separation; Purification; Use of additives, e.g. for stabilisation by physical treatment by liquid-liquid treatment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C31/00—Saturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
    • C07C31/13—Monohydroxylic alcohols containing saturated rings
    • C07C31/133—Monohydroxylic alcohols containing saturated rings monocyclic
    • C07C31/1333—Monohydroxylic alcohols containing saturated rings monocyclic with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C31/00—Saturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
    • C07C31/13—Monohydroxylic alcohols containing saturated rings
    • C07C31/137—Monohydroxylic alcohols containing saturated rings polycyclic with condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C33/00—Unsaturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
    • C07C33/36—Polyhydroxylic alcohols containing six-membered aromatic rings and other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C33/00—Unsaturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
    • C07C33/38—Alcohols containing six-membered aromatic rings and other rings and having unsaturation outside the aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/27—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation
    • C07C45/29—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation of hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/09—Preparation of carboxylic acids or their salts, halides or anhydrides from carboxylic acid esters or lactones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/16—Preparation of carboxylic acids or their salts, halides or anhydrides by oxidation
    • C07C51/21—Preparation of carboxylic acids or their salts, halides or anhydrides by oxidation with molecular oxygen
    • C07C51/255—Preparation of carboxylic acids or their salts, halides or anhydrides by oxidation with molecular oxygen of compounds containing six-membered aromatic rings without ring-splitting
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/333—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton
    • C07C67/343—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/027—Organoboranes and organoborohydrides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/10—Systems containing only non-condensed rings with a five-membered ring the ring being unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201880074452.0A 2017-11-17 2018-11-16 用于制备类视黄醇x受体-特异性类视黄醇的化合物和合成方法 Active CN111465402B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210482327.1A CN115010577A (zh) 2017-11-17 2018-11-16 用于制备类视黄醇x受体-特异性类视黄醇的化合物和合成方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762588163P 2017-11-17 2017-11-17
US62/588,163 2017-11-17
US201862671137P 2018-05-14 2018-05-14
US62/671,137 2018-05-14
PCT/US2018/061643 WO2019099920A1 (en) 2017-11-17 2018-11-16 Compounds and synthetic methods for the preparation of retinoid x receptor-specific retinoids

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202210482327.1A Division CN115010577A (zh) 2017-11-17 2018-11-16 用于制备类视黄醇x受体-特异性类视黄醇的化合物和合成方法

Publications (2)

Publication Number Publication Date
CN111465402A CN111465402A (zh) 2020-07-28
CN111465402B true CN111465402B (zh) 2022-05-24

Family

ID=66534915

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201880074452.0A Active CN111465402B (zh) 2017-11-17 2018-11-16 用于制备类视黄醇x受体-特异性类视黄醇的化合物和合成方法
CN202210482327.1A Pending CN115010577A (zh) 2017-11-17 2018-11-16 用于制备类视黄醇x受体-特异性类视黄醇的化合物和合成方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202210482327.1A Pending CN115010577A (zh) 2017-11-17 2018-11-16 用于制备类视黄醇x受体-特异性类视黄醇的化合物和合成方法

Country Status (16)

Country Link
US (3) US10590059B2 (ja)
EP (1) EP3710027A4 (ja)
JP (2) JP2021503464A (ja)
KR (1) KR20200084350A (ja)
CN (2) CN111465402B (ja)
AU (4) AU2018367653B2 (ja)
CA (1) CA3082485A1 (ja)
CL (1) CL2020001264A1 (ja)
IL (5) IL298073B2 (ja)
MX (1) MX2020005027A (ja)
MY (1) MY196734A (ja)
NZ (1) NZ763866A (ja)
PH (1) PH12020550613A1 (ja)
SG (1) SG11202003733RA (ja)
WO (1) WO2019099920A1 (ja)
ZA (3) ZA202003475B (ja)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1937244T1 (sl) 2005-09-30 2018-12-31 Io Therapeutics, Llc Zdravljenje raka s specifičnimi RXR agonisti
CN110151745A (zh) 2011-12-13 2019-08-23 Io治疗公司 使用rxr激动剂的自身免疫紊乱的治疗
CN115227826A (zh) 2016-03-10 2022-10-25 Io治疗公司 Rxr激动剂和甲状腺激素在制备用于治疗自身免疫疾病的药物中的用途
WO2019060600A1 (en) 2017-09-20 2019-03-28 Io Therapeutics, Inc. TREATMENT OF DISEASE WITH ESTERS OF SELECTIVE RXR AGONISTS
JP2021503464A (ja) 2017-11-17 2021-02-12 アイオー セラピューティクス インコーポレイテッド レチノイドｘ受容体特異的なレチノイドの調製のための化合物および合成方法
WO2023108012A1 (en) * 2021-12-07 2023-06-15 Io Therapeutics, Inc. Use of an rxr agonist and taxanes in treating her2+ cancers
AU2022407454A1 (en) 2021-12-07 2024-06-06 Board Of Regents, The University Of Texas System Use of an rxr agonist in treating drug resistant her2+ cancers
TW202400548A (zh) * 2022-03-15 2024-01-01 美商Ｉｏ治療公司 Rxr促效劑鹽形式、其多形體及其用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5917082A (en) * 1995-06-06 1999-06-29 Allergan Sales, Inc. 2,4-pentadienoic acid derivatives having retinoid-like biological activity
FR2752837B1 (fr) * 1996-09-02 1999-11-12 Cird Galderma Nouveaux composes modulateurs des recepteurs hormonaux, les compositions les comprenant et leur utilisation en therapie
US6048873A (en) * 1998-10-01 2000-04-11 Allergan Sales, Inc. Tetrahdroquinolin-2-one 6 or 7-yl, tetrahdroquinilin-2-thione 6 or 7-yl pentadienoic acid and related derivatives having retinoid-like biological activity
US6147224A (en) * 1998-10-01 2000-11-14 Allergan Sales, Inc. 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors
US6720423B2 (en) 2002-04-30 2004-04-13 Allergan, Inc. Dihydrobenzofuran and dihydrobenzothiophene 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors
US6936636B2 (en) * 2003-06-26 2005-08-30 Allergan, Inc. 5-[phenyl-tetrahydronaphthalene-2-yl dihydronaphthalen-2-yl and heteroaryl-cyclopropyl]-pentadienoic acid derivatives having serum glucose reducing activity
SI1937244T1 (sl) 2005-09-30 2018-12-31 Io Therapeutics, Llc Zdravljenje raka s specifičnimi RXR agonisti
CN101360743A (zh) * 2006-01-30 2009-02-04 Irm责任有限公司 作为ppar调节剂的多环的1,2,3,4-四氢-异喹啉衍生物和包含它们的组合物
CN110151745A (zh) 2011-12-13 2019-08-23 Io治疗公司 使用rxr激动剂的自身免疫紊乱的治疗
US10653650B2 (en) 2011-12-13 2020-05-19 Io Therapeutics, Inc. Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective RXR agonists
US20190365681A1 (en) 2015-10-31 2019-12-05 Io Therapeutics, Inc. Treatment of cancer with combinations of rxr agonists and thyroid hormones
WO2017075610A1 (en) 2015-10-31 2017-05-04 Io Therapeutics, Inc. Treatment of nervous system disorders using thyroid hormone neutral doses of rxr agonists
AU2016344018B2 (en) 2015-10-31 2019-02-28 Io Therapeutics, Inc. Treatment of nervous system disorders using combinations of RXR agonists and thyroid hormones
US10835507B2 (en) 2016-03-10 2020-11-17 Io Therapeutics, Inc. Treatment of muscular disorders with combinations of RXR agonists and thyroid hormones
CN115227826A (zh) 2016-03-10 2022-10-25 Io治疗公司 Rxr激动剂和甲状腺激素在制备用于治疗自身免疫疾病的药物中的用途
JP2021503464A (ja) 2017-11-17 2021-02-12 アイオー セラピューティクス インコーポレイテッド レチノイドｘ受容体特異的なレチノイドの調製のための化合物および合成方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Catalytic Asymmetric Cyclopropanation of Allylic Alcohols with Titanium-TADDOLate: Scope of the Cyclopropanation Reaction;Charette等;《J. Am. Chem. Soc.》;20011231;第123卷(第49期);第12168-12175页 *
Enantioselective Syntheses of Potent Retinoid X Receptor Ligands: Differential Biological Activities of Individual Antipodes;Vuligonda等;《J. Med. Chem.》;20011231;第44卷(第14期);第2298-2303页 *

Also Published As

Publication number Publication date
ZA202305927B (en) 2024-01-31
IL289991A (en) 2022-03-01
MX2020005027A (es) 2020-08-13
AU2020250208B2 (en) 2021-05-20
SG11202003733RA (en) 2020-05-28
PH12020550613A1 (en) 2021-02-22
CN111465402A (zh) 2020-07-28
AU2018367653B2 (en) 2020-11-12
US20190152888A1 (en) 2019-05-23
US10919835B2 (en) 2021-02-16
CL2020001264A1 (es) 2020-09-04
KR20200084350A (ko) 2020-07-10
IL289991B (en) 2022-12-01
IL289991B2 (en) 2023-04-01
AU2021202348B2 (en) 2023-01-05
IL298073B1 (en) 2023-10-01
IL274729A (en) 2020-07-30
WO2019099920A1 (en) 2019-05-23
EP3710027A1 (en) 2020-09-23
US20210139404A1 (en) 2021-05-13
MY196734A (en) 2023-05-03
ZA202105006B (en) 2022-12-21
NZ763866A (en) 2021-07-30
EP3710027A4 (en) 2021-09-29
AU2021202348A1 (en) 2021-05-13
JP2024028755A (ja) 2024-03-05
IL304970A (en) 2023-10-01
US10590059B2 (en) 2020-03-17
US20200190008A1 (en) 2020-06-18
CA3082485A1 (en) 2019-05-23
JP2021503464A (ja) 2021-02-12
IL283282B (en) 2022-02-01
BR112020009571A2 (pt) 2020-11-03
IL298073A (en) 2023-01-01
IL298073B2 (en) 2024-05-01
IL274729B (en) 2021-06-30
AU2018367653A1 (en) 2020-05-07
AU2020250208A1 (en) 2020-11-05
AU2023201963A1 (en) 2023-05-04
CN115010577A (zh) 2022-09-06
IL283282A (en) 2021-07-29
ZA202003475B (en) 2023-10-25

Similar Documents

Publication Publication Date Title
CN111465402B (zh) 用于制备类视黄醇x受体-特异性类视黄醇的化合物和合成方法
EP1858903A1 (de) Diarylphenoxy-aluminium-verbindungen
CN106986766B (zh) 他氟前列素的制备方法
EP3166918B1 (en) Metal-catalyzed asymmetric 1,4-conjugate addition of vinylboron compounds to 2-substituted-4-oxy- cyclopent-2-en-1-ones yielding prostaglandins and prostaglandin analogs
EP2114868A2 (en) Novel polymorphic forms of milnacipran hydrochloride
WO2019170521A1 (en) Synthesis of obeticholic acid and synthesis intermediate
CN111518110A (zh) 一种海鞘素化合物及其中间体的制备方法
CN1092759A (zh) 制备费尔巴麦特和其中间体的方法
WO2023000135A1 (en) Processes of making onapristone and intermediates thereof
EP3445745B1 (en) Process for the preparation of bimatoprost
JP4513535B2 (ja) トルテロジンの製造方法
Hayes et al. Syntheses of Both Enantiomers of 1, 7-Dioxaspiro [5.5] undecane: Pheromone Components of the Olive Fruit-Fly Dacus oleae from a New Chiral Intermediate, the (SS)-2-(p-Tolylsulfinyl) prop-2-en-1-ol
CN110746450A (zh) 一种贝前列素钠关键中间体的合成方法
CN116867762A (zh) 环己烯酮化合物的制造方法
WO2010143150A2 (en) Process for stereoselective preparation of an intermediate of protease inhibitors
AU2007314966A1 (en) Process for production of 1-hydroxy-19-norcyclovitamin D derivative and intermediate for the production
JPH10265420A (ja) シクロヘキシリデン誘導体の製造方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40034387

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant